Clinical Trial Update: PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum [NA]

View source ↗

Summary

A completed clinical trial evaluating the pharmacodynamic phosphate-binding properties of K2CG Chewing Gum for hyperphosphatemia in chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• K2CG Chewing Gum

Snippet

Sponsor: Denver Nephrologists, P.C. | Conditions: Hyperphosphatemia, Chronic Kidney Disease | NA | Status: COMPLETED